| Cardiovascular Risk Management |
1 |
1 |
| Hypertension |
0 |
0.81 |
| Coronary Artery Disease (CAD) |
0 |
0.79 |
| Heart |
0 |
0.6 |
| Biologic Therapy |
0 |
0.54 |
| Heart Failure (HF) |
0 |
0.51 |
| Cardiomyopathy |
0 |
0.49 |
| Oxidative Stress |
0 |
0.48 |
| Antioxidant |
0 |
0.44 |
| Cerebrovascular Accident |
0 |
0.38 |
| Stress |
0 |
0.36 |
| Gout |
0 |
0.3 |
| Xanthines |
0 |
0.2 |
| Angina Pectoris |
0 |
0.17 |
| Acute Coronary Syndrome |
0 |
0.16 |
| NHS |
0 |
0.14 |
| Atherosclerosis |
0 |
0.1 |
| Lipids Management |
0 |
0.09 |
| Toxicology |
0 |
0.09 |
| Artery |
0 |
0.08 |
| Nitric Oxide |
0 |
0.08 |
| UK Site Content |
0 |
0.08 |
| Chest Pain |
0 |
0.07 |
| Peripheral Artery Disease |
0 |
0.07 |
| Targeted Cancer Therapy |
0 |
0.07 |
| Angiotensin II Receptor Blockade |
0 |
0.06 |
| ACE Inhibitor |
0 |
0.04 |
| Beta-Adrenergic Agonist |
0 |
0.04 |
| Biomarker |
0 |
0.04 |
| Blood |
0 |
0.04 |
| Cancer |
0 |
0.04 |
| Cardiovascular disease |
0 |
0.04 |
| Europe |
0 |
0.04 |
| Exercise |
0 |
0.04 |
| Health Care Services |
0 |
0.04 |
| Infarction |
0 |
0.04 |
| Ischemia |
0 |
0.04 |
| Left Ventricular Hypertrophy (LVH) |
0 |
0.04 |
| Myocardial Infarction (MI) |
0 |
0.04 |
| North Carolina |
0 |
0.04 |
| Pain |
0 |
0.04 |
| Pain Management |
0 |
0.04 |
| Pathogenesis |
0 |
0.04 |
| Quality of Life |
0 |
0.04 |
| Receptors |
0 |
0.04 |
| Stable Angina |
0 |
0.04 |
| Statins |
0 |
0.04 |
| Stevens-Johnson Syndrome |
0 |
0.04 |
| Thorax |
0 |
0.04 |
| Toxic Epidermal Necrolysis |
0 |
0.04 |
| Transient Ischemic Attack |
0 |
0.04 |
| Transplant Evaluation |
0 |
0.04 |